CURE’s Chronic Lymphocytic Leukemia (CLL) page features the latest cancer news and updates on CLL Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in chronic lymphocytic leukemia.
This article was sponsored by AstraZeneca.
An interview with Dr. Jennifer K. Lue, Assistant Professor of Medicine, Center for Lymphoid Malignancies, Division of Hematology and Oncology, Columbia University Irving Medical Center
May 4th 2020
Patients with chronic lymphocytic leukemia are at risk for the worst of COVID-19 symptoms, but going on the cancer journey has prepared them for the pandemic.
May 1st 2020
Social distancing measures are keeping people apart, but that hasn't stopped some patients with CLL from finding a new sense of community.
April 30th 2020
The COVID-19 Pandemic has changed immediate treatment for patients with chronic lymphocytic leukemia, but it is also impacting the clinical trials looking to improve the future treatment for these patients.
April 27th 2020
Dr. Richard Pazdur, director of the Food and Drug Administration’s Oncology Center of Excellence, has noted that the agency is committed to expediting oncology drug development despite the challenges posed by the COVID-19 pandemic.
April 21st 2020
The Food and Drug Administration, under its global Project Orbis, approved the combination of Imbruvica and Rituxan for patients with CLL and SLL.
April 20th 2020
Calquence (acalabrutinib) may be a safe and effective treatment option for patients with relapsed or refractory chronic lymphocytic leukemia, according to the updated phase 2 results of an ongoing study.
April 17th 2020
First validated prognostic score offers valuable insights for patients with chronic lymphocytic leukemia who are prescribed active surveillance.
April 8th 2020
Bruton tyrosine kinase (BTK) inhibitors and other new drugs are improving outcomes for patients with CLL.
April 1st 2020
The COVID-19 pandemic's impact is being felt all throughout the cancer community, and experts from the CLL Society hosted a webinar to discuss the specific impacts of the pandemic on patients with chronic lymphocytic leukemia.
March 21st 2020
Patients with relapsed or refractory CD19-positive cancers experienced complete responses with no major side effects following treatment with CAR-NK cell therapy.
March 3rd 2020
Newer medications that displace chemotherapy aim directly at mutations in the Bruton tyrosine kinase gene and help patients with CLL live longer.